Intravenous bisphosphonates for postmenopausal osteoporosis
Numerous clinical studies have shown bisphoshonates (BPs) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. The use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Medknow Publications
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082804/ |
| id |
pubmed-3082804 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-30828042011-04-27 Intravenous bisphosphonates for postmenopausal osteoporosis Mottaghi, Peyman Review Article Numerous clinical studies have shown bisphoshonates (BPs) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. The use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from gastrointestinal side effect or frequently dosed oral regimens. To improve upon the suboptimal therapeutic compliance in postmenopausal women, newer, longer-acting intravenous formulations of BPs has been approved for intermittent administration in postmenopausal women. These preparations would become an option for patients who can not tolerate oral BPs or it was ineffective in increasing their bone density. Medknow Publications 2010 /pmc/articles/PMC3082804/ /pubmed/21526078 Text en © Journal of Research in Medical Sciences http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Mottaghi, Peyman |
| spellingShingle |
Mottaghi, Peyman Intravenous bisphosphonates for postmenopausal osteoporosis |
| author_facet |
Mottaghi, Peyman |
| author_sort |
Mottaghi, Peyman |
| title |
Intravenous bisphosphonates for postmenopausal osteoporosis |
| title_short |
Intravenous bisphosphonates for postmenopausal osteoporosis |
| title_full |
Intravenous bisphosphonates for postmenopausal osteoporosis |
| title_fullStr |
Intravenous bisphosphonates for postmenopausal osteoporosis |
| title_full_unstemmed |
Intravenous bisphosphonates for postmenopausal osteoporosis |
| title_sort |
intravenous bisphosphonates for postmenopausal osteoporosis |
| description |
Numerous clinical studies have shown bisphoshonates (BPs) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. The use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from gastrointestinal side effect or frequently dosed oral regimens. To improve upon the suboptimal therapeutic compliance in postmenopausal women, newer, longer-acting intravenous formulations of BPs has been approved for intermittent administration in postmenopausal women. These preparations would become an option for patients who can not tolerate oral BPs or it was ineffective in increasing their bone density. |
| publisher |
Medknow Publications |
| publishDate |
2010 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082804/ |
| _version_ |
1611450569149382656 |